Dimerix Limited (AU:DXB) has released an update.
Dimerix Limited has announced the approval of their DMX-200 Paediatric Investigation Plan by the UK’s Medicines and Healthcare products Regulatory Agency, aiming to include children aged 12-17 in their Phase 3 FSGS kidney disease study. This regulatory milestone aligns with the US and European paediatric plans and could lead to market authorisation for paediatric use, addressing a critical need in treating a leading cause of kidney failure in children.
For further insights into AU:DXB stock, check out TipRanks’ Stock Analysis page.
